<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119417</url>
  </required_header>
  <id_info>
    <org_study_id>091344</org_study_id>
    <nct_id>NCT01119417</nct_id>
  </id_info>
  <brief_title>The Role of Endothelin in the Supine Hypertension of Autonomic Failure</brief_title>
  <official_title>The Role of Endothelin in the Supine Hypertension of Autonomic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that endothelin plays a role in the&#xD;
      pathogenesis of supine hypertension in pure autonomic failure by increasing vascular&#xD;
      resistance. To gauge its contribution to blood pressure regulation, pure autonomic failure&#xD;
      and multiple system atrophy patients with supine hypertension will undergo a medication&#xD;
      testing with the endothelin blocker, BQ123. We will compare the hemodynamic effects between&#xD;
      PAF and MSA patients. Our primary endpoint will be the decrease in blood pressure during the&#xD;
      administration of this compound.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiologic mechanisms causing supine hypertension in patients with autonomic&#xD;
      failure are not completely understood.In MSA patients, supine hypertension may be explained&#xD;
      by residual sympathetic tone, possibly acting on hypersensitive adrenoreceptors and&#xD;
      unstrained by the lack of baroreflex modulation. In contrast, the pathogenesis of&#xD;
      hypertension in PAF remains unknown. Hypertension in these patients is not related to&#xD;
      intravascular volume, residual sympathetic tone, or renin mechanisms. Increased vascular&#xD;
      resistance is the underlying hemodynamic mechanism. The driving force of this increased&#xD;
      vascular tone, however, is not known.&#xD;
&#xD;
      We hypothesize that endothelin (ET)-l contributes to the increased vascular resistance in&#xD;
      pure autonomic failure patients with supine hypertension. To gauge its contribution to blood&#xD;
      pressure regulation, we will induce endothelin blockade with acute systemic administration of&#xD;
      BQ123 in an ascending dose regimen (25, 50, 100 and 300 nmol/min) and we will compare the&#xD;
      hemodynamic effects between PAF and MSA patients.&#xD;
&#xD;
      Subjects will be studied on 3 different days, one with saline (placebo) and two with BQ123: a&#xD;
      'low dose' day (25 and 50 nmol/min infusions separated by 75 min) and a 'high dose' day (100&#xD;
      and 300 nmol/min infusions separated by 75 min). The order of the placebo day will be&#xD;
      randomized in a single-blinded manner so that each subject receives it on a different visit.&#xD;
      The order of the BQ123 study days will be always the same, starting with the low dose. If SBP&#xD;
      drops by &gt;40 mm Hg or SBP &lt; 130 mm Hg during the monitoring period after the first or second&#xD;
      infusion, the following dose(s) of BQ123 will not be given and patients will receive normal&#xD;
      saline until the study ends.&#xD;
&#xD;
      Ganglionic Blockade with Trimethaphan (optional study day):&#xD;
&#xD;
      The purpose of this study day is to determine the level of residual sympathetic tone that&#xD;
      contributes to supine hypertension in each autonomic failure patient by inducing transient&#xD;
      withdrawal of the autonomic nervous system. This approach would allow us to identify patients&#xD;
      in whom supine hypertension is not driven by sympathetic tone and thus, better characterize&#xD;
      the role of endothelin in the hypertension of these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants were enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">May 2010</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">May 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic BP</measure>
    <time_frame>0 -4 hr post infusion</time_frame>
    <description>Change from baseline in systolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac output, stroke volume and systemic vascular resistance</measure>
    <time_frame>0-4 hr post infusion</time_frame>
    <description>Percent change from baseline in hemodynamic parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <condition>Pure Autonomic Failure</condition>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>BQ123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endothelin blocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ123</intervention_name>
    <description>Low dose day: 25 nmol/min, single IV infusion for 15 min.</description>
    <arm_group_label>BQ123</arm_group_label>
    <other_name>BQ-123 sodium salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ123</intervention_name>
    <description>Low dose day: 50 nmol/min, single IV infusion for 15 min</description>
    <arm_group_label>BQ123</arm_group_label>
    <other_name>BQ-123 sodium salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bq123</intervention_name>
    <description>High dose day: 100 nmol/min, single IV infusion for 15 min.</description>
    <arm_group_label>BQ123</arm_group_label>
    <other_name>BQ-123 sodium salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ123</intervention_name>
    <description>High dose day: 300 nmol/min, single IV infusion for 15 min.</description>
    <arm_group_label>BQ123</arm_group_label>
    <other_name>BQ-123 sodium salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>2-3 IV saline infusions for 15 min each.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Normal saline, 0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with autonomic failure and supine hypertension from all races, who are in the&#xD;
             hospital participating in the study &quot;The Evaluation and Treatment of Autonomic&#xD;
             Failure&quot; (IRB# 000814).&#xD;
&#xD;
          -  Supine hypertension, defined as a systolic blood pressure &gt;150 mm Hg or diastolic&#xD;
             blood pressure &gt; 90 mm Hg.&#xD;
&#xD;
          -  Males and females, between 18-85yr.&#xD;
&#xD;
          -  Provide written informed consent to participate in the study and understand that they&#xD;
             may withdraw their consent at any time without prejudice to their future medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver&#xD;
             impairment, history of stroke or myocardial infarction).&#xD;
&#xD;
          -  History of serious allergies or asthma.&#xD;
&#xD;
          -  In the investigator's opinion, have clinically significant abnormalities on clinical,&#xD;
             mental examination or laboratory testing.&#xD;
&#xD;
          -  All medical students.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>supine Hypertension</keyword>
  <keyword>autonomic failure</keyword>
  <keyword>BQ123</keyword>
  <keyword>BQ-123</keyword>
  <keyword>endothelin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

